David Rodeberg, MD
Disclosures: I/we have no financial relationships to report.

Dr. David Rodeberg (ECU Physicians Pediatric Surgery)

Dr. David Rodeberg is a member of the East Carolina University Department of Surgery, He is the Verneda and Clifford Kiehn Professor of Pediatric Surgery and Chief, Division of Pediatric Surgery. In addition to his role on the ECU faculty, Dr. Rodeberg serves as Co-Director and Surgeon-in-Chief of the Maynard Children's Hospital. He has a bachelor’s degree from Viterbo College in Wisconsin and a medical degree from the University of Wisconsin. He completed a general surgery internship and residency at the University of Cincinnati and a fellowship in pediatric surgery at The Johns Hopkins. From there, he worked on the faculty of the Mayo Clinic in Minnesota and subsequently the Children’s Hospital of Pittsburgh and the University Of Pittsburgh School Of Medicine.

Dr. Rodeberg has been involved in both translational and clinical cancer research. His translational research initially involved the development of peptide-based dendritic cell vaccine immunotherapy and immune modulation utilizing a CpG oligodeoxynucleotide adjuvant for the treatment of rhabdomyosarcoma (RMS). However, like many researchers exploring anti-tumor vaccines, he came to realize that the limiting factor for an effective vaccine was not dependent on the presence of antigen, or the induction of an immune response to an antigen, but was dependent on the tumor and its microenviroment. Subsequently his work continued in sarcomas but shifted to the receptor/ligand complexes involved in tumor cell: immune cell interactions including NKG2D:MICA and Notch:Delta/Jagged.

Dr Rodeberg’s clinical research has also involved pediatric sarcomas. In 2000 he became involved in the Intergroup Rhabdomyosarcoma Study Group (IRSG, now called the Soft Tissue Sarcoma (STS) committee and the Children’s Oncology Group (COG). The STS is involved in the generation, performance and analysis of national clinical treatment trials and biologic studies for pediatric RMS and non-rhabdomyosaromas. The STS is composed of members from each of the clinical disciplines and also basic science tumor biologists and pathologists. Dr. Rodeberg has been appointed as a member of both the COG Surgical Steering Committee and the STS Steering Committee. In addition, he is the Surgical Chair for the STS committee. He is the surgical principal investigator for several of the NIH sponsored RMS treatment protocols.